Procrit: Interim Phase IV data

Interim analysis from an open-label, U.S. Phase IV trial in 358 patients showed that epoetin alfa

Read the full 163 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE